mail
versión imprimible
 
 

2nd ALS Drug Development Summit

Evvnt Promotion / evvnt
-
16.05.2023 - 18.05.2023  Hilton Boston Logan Airport, One Hotel Drive, 02128 Boston, Massachusetts, USA
9:00 am - 4:30 pm
 
Temas de la conferencia
Following the approval of Amylyx's Relyvrio in the US and Canada and further FDA decisions on the horizon in 2023, the ALS drug development landscape is gaining momentum and positivity. With booming pharma investment and new biotechs entering the field, there are still crucial translational challenges to address to bridge the gap and see clinical success for the wider ALS patient population.
Organizador profesional (PCO)
Hanson Wade
Observaciones
URL:
Brochure: https://go.evvnt.com/1485150-3?pid=4832

Speakers: Alain Moussy, Co-Founder and Chief Executive Officer, AB Science, and more.
 

Información e inscripción:

https://go.evvnt.com/1485150-2?pid=4832
Ms. Erin Thomas
 
Categorías
Medicina General
Idioma
Inglés
Cuota del Congreso
USD 2599.00 - USD 5297.00
Cantacto organizador
83 Great Titchfield Street
W1W 6RH London
United Kingdom
 
"Going International fomenta el acceso a la educación y a la formación continua independientemente de fronteras sociales, geográficas y nacionales."

Österreichisches Rotes KreuzEuropean Public Health Association (EUPHA)Centro per la Formazione Permanente e l'Aggiornamento del Personale del Servizio SanitarioAlumni Club Medizinische Universität WienHelix - Forschung & Beratung WienOÖ Gebietskrankenkasse, Referat für Wissenschaftskooperation Österreichische Gesellschaft für Public HealthEuropean Health Forum Gastein